Sandoz Group AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Oxymorphone

First Posted Date: 2009-03-06

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 50

Registration Number: NCT00857428

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Pain

Interventions: Drug: oxymorphone hydrochloride
Drug: Opana

First Posted Date: 2009-03-06

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 32

Registration Number: NCT00857142

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: HX575, solution for injection (s.c.)
Drug: ERYPO®, Janssen-Cilag, solution for injection (s.c.)

First Posted Date: 2008-07-09

Last Posted Date: 2017-09-05

Lead Sponsor: Sandoz

Target Recruit Count: 114

Registration Number: NCT00711958

Locations: 🇷🇴
Oncologic Institute, Cluj-Napoca, Romania
🇩🇪
Gemeinschaftspraxis mit Schwerpunkt Hämatologie und Internistische Onkologie, Bad Soden, Germany
🇩🇪
Klinikum Nürnberg, 5. Medizinische Klinik Haus 12, Zimmer Nr. 13, Nürnberg, Germany

and more 16 locations

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Phase 3

Terminated

Conditions: Anemia
Chronic Renal Insufficiency

Interventions: Drug: HX575 recombinant human erythropoietin alfa
Drug: ERYPO

First Posted Date: 2008-06-19

Last Posted Date: 2018-02-05

Lead Sponsor: Sandoz

Target Recruit Count: 337

Registration Number: NCT00701714

Locations: 🇦🇹
Diakonissen KH Salzburg, Salzburg, Austria
🇦🇹
LKH Steyr, Steyr, Austria
🇦🇹
Krankenanstalt der Stadt Wien, Wien, Austria

and more 113 locations

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: HX575 epoetin alfa Hexal AG
Drug: ERYPO®, Janssen-Cilag

First Posted Date: 2008-04-25

Last Posted Date: 2023-07-03

Lead Sponsor: Sandoz

Target Recruit Count: 478

Registration Number: NCT00666835

Locations: 🇦🇹
Allgemeines Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria
🇦🇹
Dialyseinstitut Graz GmbH, Graz, Austria
🇦🇹
Universitätsklinik Innsbruck, Klinische Abteilung für Nephrologie, Innsbruck, Austria

and more 24 locations

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

Phase 4

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: HX575 recombinant human erythropoietin alfa

First Posted Date: 2008-03-10

Last Posted Date: 2017-07-11

Lead Sponsor: Sandoz

Target Recruit Count: 1695

Registration Number: NCT00632125

Locations: 🇺🇦
Ternopilska Oblasna Klinichna Likarnia, Viddilennia Nefrologii ta Gemodializu, Ternopil, Ukraine
🇦🇹
Landeskrankenhaus Feldkirch, Feldkirch, Austria
🇦🇹
Universitätsklinik für Innere Medizin III, Wien, Austria

and more 101 locations

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Phase 4

Completed

Conditions: Small for Gestational Age

Interventions: Drug: Omnitrope

First Posted Date: 2007-10-02

Last Posted Date: 2024-03-12

Lead Sponsor: Sandoz

Target Recruit Count: 278

Registration Number: NCT00537914

Locations: 🇷🇴
Sandoz Investigational Site, Iaşi, Romania

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

Phase 1

Completed

Conditions: HIV Infections
Cytopenias

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002006

Locations: 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

Phase 1

Completed

Conditions: HIV Infections
Cytopenias

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002258

Locations: 🇺🇸
New England Deaconess Hosp, Boston, Massachusetts, United States

A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis

Phase 1

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Sandoz

Registration Number: NCT00002016

Locations: 🇺🇸
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
🇺🇸
Univ TX Galveston Med Branch, Galveston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy